Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children

Pediatrics International

Volumn 41, Issue 1, 1999, Pages 28-31

  Sedef Tunaoglu F ^a,b   Türktaş, Ipek ^a   Olguntürk, Rana ^a   Demirsoy, Sadik ^a  

^a GAZI UNIVERSITY   (Turkey)

^b Gazi Hastanesi   (Turkey)

Author keywords

Asthma; Cardiac side effect; Salineterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; POTASSIUM; SALMETEROL;

ADOLESCENT; ARTICLE; ASTHMA; BLOOD PRESSURE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART DISEASE; HEART EJECTION FRACTION; HEART OUTPUT; HEART PALPITATION; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE EXTRASYSTOLE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SUPRAVENTRICULAR PREMATURE BEAT; TREMOR;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; CARDIAC OUTPUT; CHILD; DRUG MONITORING; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART RATE; HUMANS; MALE; STROKE VOLUME;

EID: 0033067188     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200x.1999.01009.x     Document Type: Article

References (27)

1. Johnson M. The preclinical pharmacology of salmeterol: Bronchodilator effects. Eur. Respir. Rev. 1991; 1: 253-6.
2. Devoy MAB, Fuller RW, Palmer JBD. Are there any detrimental effects of the use of inhaled long-acting β2 agonists in the treatment of asthma? Chest 1995; 107: 1116-24.
3. Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Ann. Allergy 1993; 70: 316-22.
4. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur. Respir. J. 1992; 5: 1062-7.
5. Maconochie JG, Forster JK. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br. J. Clin. Pharmacol. 1992; 33: 342-5.
6. Johnson M, Butchers PR, Coleman RA et al. The pharmacology of salmeterol. Life Sci. 1993; 52: 2131-3.
7. Feigenbaum H. Echocardiography, 5th edn. Lea & Febiger, Malvern, 1994.
8. Bradshaw J, Brittain RT, Coleman RA et al. The design of salmeterol: A long-acting selective β2 adrenoreceptor. Br. J. Pharmacol. 1987; 92: 590P.
9. Ball DI, Coleman RA, Denzer LH, Nials AT, Sheldrick KE. In vitro characterization of the β2-adrenoreceptor agonist, salmeterol. Br. J. Pharmacol. 1987; 92: 591P.
10. Kayaalp O. Tybbi Fannakoloji 3rd edn. Ulucanlar, Ankara. 1985; 1412-25.
11. Higgins Rm, Cookson WOCM, Lane DJ et al. Cardiac arrhythmias caused by nebulised beta-agonist therapy. Lancet 1987; 10: 863-4.
12. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br. Med. J. 1993; 306: 1034-7.
13. Pearce N, Crane J, Burgess C, Jackson R, Beasley R. Beta agonist and asthma mortality: Deja vu. Clin. Exp. Allergy 1991; 21: 401-10.
14. Hall JP, Woodhead MA, Johnson IDA. Effect of high-dose salbutamol on cardiac rhythm in severe chronic airflow obstruction: A controlled study. Respiration 1994; 61: 214-18.
15. Incalzi R, Pistelli R, Fuso L, Cochi A, Bonetti M, Giordano A. Cardiac arrhythmias and left ventricular function in respiratory failure from chronic obstructive pulmonary disease. Chest 1990; 97: 1092-7.
16. Beder SD. Ambulatory electrocardiography. In: Adams FH, Emmanoulides GC, Riemenschneider TA, eds. Moss' Heart Disease in Infants, Children, and Adolescents, 4th edn. Williams & Wilkins, Baltimore, 1989; 1003-8.
17. Park MK. Pediatric Cardiology for Practitioners, 3rd edn. Mosby, St Louis, 1996.
18. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular and hypokalemic effects of fenoterol, salbutamol and terbutaline in asthma. Lancet 1990; 336: 1396-9.
19. Haalboom JRE, Deenstra M, Struyvenberg A. Hypokalemia induced by inhalation of fenoterol. Lancet 1985; 1: 1125-7.
20. Tveskov C, Djurhuns MS, Klitgaard NAH, Egstrup K. Potassium and magnesium distribution, ECG changes and ventricular ectopic beats during β2-adrenergic stimulation with terbutaline in healthy subjects. Chest 1994; 106: 1654-9.
21. Nathan RA, Seltzer JM, Kemp JP et al. Safety of salmeterol in the maintenance treatment of asthma. Ann. Allergy Asthma Immunol. 1995; 75: 243-8.
22. Nathan RA, Liddle R, Alexander WJ. Yancey S. Salmeterol safety and tolerability. J. Allergy Clin. Immunol. 1994; 1: 248.
23. Weinberger M. Salmeterol for the treatment of asthma. Ann. Allergy, Asthma Immunol. 1995; 75: 209-11.
24. Jones K. Salmeterol in the management of paediatric asthma. Respiratory Med. 1994; 88: 639-43.
25. Boner A. Salmeterol: Long-term studies in children. Eur. Respir. J. 1993; 5 (Suppl. 15); S318.
26. Green CP, Price JT. Prevention of exercise-induced asthma by inhaled xinofoate. Arch. Dis. Child. 1992; 67: 1014-17.
27. Ruggins NR, Milner AD. The prolonged effect of salmeterol hydroxynapthoate on exercise-induced bronchoconstriction (EIB) in asthmatic children. Am. Rev. Respir. Dis. 1991; 143: A22.